Overview
TECX market data
Price History
TECX price chart · 3M
- O
- 36.04
- H
- 38.00
- L
- 36.04
- C
- 36.88
- Vol
- 17,152.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $36.04
- Previous Close
- $35.99
- Day High
- $38.00
- Day Low
- $36.04
- 52 Week High
- $38.71
- 52 Week Low
- $26.56
- 7 Day Return
- +2.34%
- 30 Day Return
- +23.68%
- 90 Day Return
- +18.43%
- 1 Year Return
- +37.00%
- Daily Notional Volume
- $632.6K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.05 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.29 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.39 – $39.53 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $685M · P/B 1.55.
Company News
Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $93Benzinga · Aug 7, 2026, 1:58 PM
Tectonic Therapeutic Q2 EPS $(1.18) Beats $(1.37) EstimateBenzinga · Aug 6, 2026, 9:44 PM
8-K filing — Tectonic Therapeutic, Inc. (TECX)SEC EDGAR · Jun 10, 2026, 9:08 PM
Tectonic Therapeutic Completes Enrollment For The APEX Trial, A 24-Week Phase 2 Clinical Trial Evaluating The Safety And Efficacy Of TX45 In Patients With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction; APEX Phase 2 Trial Enrolled 191 Patients Across 14 Countries, With ~72% Of Patients In The Enriched Population Of CpcPH With A Pulmonary Vascular Resistance >3 WU At BaselineBenzinga · Jun 10, 2026, 8:10 PM